摘要
男性乳腺癌(male breast cancer,MBC)在我国的发病率为0.4/100 000,高发年龄70~79岁,是一种有着较强地域分布性和种族选择性的少见乳腺癌类型。发病与BRCA突变、家族史、男性乳腺发育及体内雌雄激素比升高等因素密切相关。MBC治疗是以手术为主的综合性治疗,由于病例数量有限,可借鉴的药物治疗循证医学证据很少,MBC的药物治疗以及研究主要参考女性乳腺癌。绝大多数男性乳腺癌激素受体阳性,内分泌治疗敏感。男性乳腺癌内分泌治疗的主要尝试有:他莫昔芬、芳香化酶抑制剂、促性腺激素释放激素类似物、氟维司群、雌孕激素、糖皮质激素、抗雄激素、睾丸切除等。基于目前循证医学证据,他莫昔芬是男性乳腺癌内分泌治疗的首要选择。
The incidence of Male breast cancer（ MBC） in China is 0. 4/100 000. Common onset age was 70 to79 years old. MBC is a kind of breast cancer which tends to be influenced by regional distribution and racial sdifference.BRCA mutations,family history,and male breast development are frequently seen risk factors. Surgery is the main therapy. Due to the limited number of cases and very little evidence of evidence-based medicine,therapy and research of MBC mainly refer to breast cancer in women. Most of the male breast cancers are hormone receptor-positive,and are sensitive to endocrine therapy. The endocrine treatment of male breast cancer include： tamoxifen,aromatase inhibitors,gonadotropinreleasing hormone analogue,fulvestrant,estrogen,glucocorticoid,and rogen deprivation therapy,orchiectomy,etc. According to evidence-based medicine,tamoxifen is the first choice in endocrine therapies for male breast cancer.
作者
魏洪亮
肖晶晶
凌瑞
Wei Hongliang;Xiao Jingjing;Ling Rui(Department of Thyroid-Breast- Vascular Surgery,Xijing Hospital, The Fourth Military Medical University, X i ＇an 710032, Shanxi , China)
出处
《肿瘤预防与治疗》
2018年第3期227-231,共5页
Journal of Cancer Control And Treatment
基金
国家科学自然基金(编号:NO.81572917)
关键词
男性乳腺癌
内分泌治疗
他莫昔芬
Male breast cancer
Disease characteristics
Endocrine therapy
Tamoxifen
